These immunotoxins, Rova-GrB (rovalpituzumab-granzyme B) and Rova-Typh (rovalpituzumab-typhoid), are designed to enter cancer cells and release toxins, namely, typhoid toxin and granzyme B, to induce cancer cell destruction. Here, GZMB is linked to cancer.